

April 10, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, “G” Block
Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the ‘Listing Regulations’).

Pursuant to the Regulation 30 (read with Part A of Schedule III) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“Listing Regulations”), we wish to inform you that Sharon Bio-Medicine Limited (**material subsidiary of the Company**), in its Board Meeting held on Wednesday, April 10th, 2024, has approved the purchase of a land and pursuant to Board approval dated April 10th, 2024, Sharon Bio-Medicine Limited has entered into an agreement on April 10, 2024 for purchasing of land admeasuring 4,410 sq. mtr. (5.86 Bigha) situated at Khasra number 1031 & 1032, Central Hope Town, Selaqui, Dehradun in the State of Uttrakhand.

Further it was informed by the Sharon Bio-Medicine Limited that abovementioned land is situated adjacent to boundary of their existing manufacturing facilities at Dehradun.

The details required to be furnished under Regulation 30 of Listing Regulations read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 (“Master Circular”) and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 issued thereunder have been attached as an **Annexure-1**.

The aforesaid information is also being placed on the website of the Company at www.innovacaptab.com

We request you to take the same on your record.

Thanking you,

Yours faithfully,

For **Innova Captab Limited**

Neeharika Shukla
Company Secretary & Compliance Officer
Membership No.: A42724

Encl: A/a

Annexure 1

Details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023:

S.No.	Particulars	Details
1.	Date on which the agreement for purchase has been entered into	April 10, 2024
2.	Details of the address where land is situated	Khasra number 1031 & 1032, Central Hope Town, Selaqui, Dehradun, Uttrakhand admeasuring 4410 sq. mtr. (5.86 Bigha). (The land is situated adjacent to boundary of Sharon Bio-Medicine's existing manufacturing facilities at Dehradun)
3.	The expected date of completion of Purchase	Within 4 months from date of Agreement i.e April 10, 2024
4.	Consideration paid for purchase	₹ 4,12,73,150.00 (Rupees Four Crore Twelve Lakh Seventy Three Thousand One Hundred Fifty Only)
5.	Whether buyer belong to the promoter/ promoter group/group companies. If yes, details thereof	The Buyer does not belongs to the promoter/promoter group/ group companies.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm's length	Sharon Bio-Medicine Limited (material subsidiary of the Company) has entered into an agreement to purchase land. Other than those stated above, the transaction does not fall within the purview of Related Party Transactions.